TITLE

BIOVITRIM/SANTHERA SIGN PACT FOR DEVELOPING DPP-IV

PUB. DATE
October 2005
SOURCE
Worldwide Biotech;Oct2005, Vol. 17 Issue 10, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on an exclusive license and collaboration agreement signed by Biovitrum with Santhera for the development of DPP-IV inhibitors for the treatment of type 2 diabetes and other metabolic diseases as of October 2005. Terms of the deal; Background on the DPP-IV inhibitors; Information on Biovitrum.
ACCESSION #
18393350

 

Related Articles

  • SANTHERA/BIOVAIL TO DEVELOP JP-1730/FIPAMEZOLE IN AMERICA.  // Worldwide Biotech;Oct2009, Vol. 21 Issue 10, p3 

    The articles reports that Santhera Pharmaceuticals and Biovail Corporation have signed a license agreement for Santhera's JP-1730/fipamezole. It states that Biovail, which is considered a key player in the area of neurodegenerative disorders, acquired the U.S. and Canadian rights to develop and...

  • Deal watch : Santhera licenses novel dyskinesia therapy to Biovail.  // Nature Reviews Drug Discovery;Oct2009, Vol. 8 Issue 10, p762 

    The article discusses the agreement between Biovail Laboratories Inc. and Santhera Pharmaceuticals Holding AG entitling Biovail the rights to develop and commercialize fipamezole also known as JP-1730 in Canada an U.S. It mentions that fipamezole is generated to treat levodopa-induced dyskinesia...

  • Santhera, Biovail in $192M Pact for Parkinson's Drug Fipamezole. Sheridan, Cormac // BioWorld International;8/26/2009, Vol. 14 Issue 34, p1 

    The article reports on a partnership formed by Santhera Pharmaceuticals Holding AG with Biovail Corp. for the Parkinson's drug fipamezole. Under the collaboration, Santhera could receive up to 192 million U.S. dollars from Biovail worth of up-front, development, regulatory and commercial...

  • Santhera In-Licenses Novartis Drug For Muscular Dystrophy. Sheridan, Cormac // BioWorld International;7/4/2007, Vol. 12 Issue 27, p1 

    The article reports that Santhera Pharmaceuticals AG has closed a licensing deal with Novartis AG for the use of omigapil (SNT-317). SNT-317 is a compound that has a potential to treat predominant forms of congenital muscular dystrophy. Santhera would gain access to preclinical and clinical data...

  • Type 2 diabetes mellitus.  // Formulary;Aug2008, Vol. 43 Issue 8, p304 

    The article offers information on some drugs recommended for the treatment of type 2 diabetes mellitus. Alogliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, is recommended as monotherapy or in combination with other antidiabetic agents. Dapagliflozin/metformin, an oral combination of...

  • Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes. Zito, S. W.; Shinde, J.; Chen, I-C. S.; Taldone, T.; Barletta, M. // Current Bioactive Compounds;Aug2008, Vol. 4 Issue 2, p68 

    In this review, we focus on the chemicals used in the current treatment of type 2 diabetes and discuss some potentially viable, promising targets in the management of this metabolic syndrome, with a special mention to some naturally occurring bioactive compounds. Non-insulin dependent diabetes...

  • The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes. Scheen, Andr� J. // Current Protein & Peptide Science;Feb2009, Vol. 10 Issue 1, p56 

    Type 2 diabetes is closely related to abdominal obesity and is generally associated with other cardiometabolic risk factors, resulting in a high incidence of cardiovascular complications. Several animal and human observations suggest that the endocannabinoid (EC) system is overactivated in...

  • PPAR-γ action: it's all in your head. Myers, Martin G.; Burant, Charles F. // Nature Medicine;May2011, Vol. 17 Issue 5, p544 

    In this article the authors discuss aspects on the role of Thiazolidinedione (TZD), a drug that targets peroxisome proliferator-activated receptor-É£ (PPAR-É£) to prevent type 2 diabetes, on adipogenesis. They analyze two research studies which point that other tissues like the brain, which...

  • Incretin-Based Therapies in Patients with Type 2 Diabetes. Freeman, Jeffrey S. // Current Drug Therapy;May2010, Vol. 5 Issue 2, p75 

    Type 2 diabetes mellitus (T2DM) is a highly prevalent and progressive metabolic disease associated with significant morbidity and mortality. While glycemic control remains the cornerstone of disease treatment, successful T2DM management requires consideration of several comorbid risk factors...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics